Dual-Purpose Drug for Aging and Lung Disease Alters Blood Markers

Trial Links Lung Fibrosis Treatment to Slower Biological Aging

An experimental lung medication reduced blood markers of biological age in human participants during an early clinical trial.

Researchers evaluated rentosertib, an investigational compound developed by Insilico Medicine to treat idiopathic pulmonary fibrosis (IPF).

The trial examined whether treating organ scarring could also alter broader aging processes in the body.

• The compound inhibits Traf2- and Nck-interacting kinase (TNIK).
• This protein regulates both scar tissue growth in lungs and shared biological aging pathways.
• A study published in Nature Biotechnology reported that treated patients showed molecular profiles associated with a younger biological age than participants on placebo.

Six Proteomic Clocks Measured Circulating Blood Proteins

Six distinct proteomic aging clocks identified younger biological profiles in patients who received rentosertib compared to placebo.

These tools estimate biological age by measuring thousands of proteins circulating in serum.

Proteomic clocks adjust quickly to medical interventions, whereas deoxyribonucleic acid (DNA) methylation clocks can yield inconsistent readings.

• The Phase 2a trial enrolled 42 IPF patients over a 12-week intervention window.
• Investigators assigned subjects to a placebo or one of three dosing arms: 30 milligrams once daily, 30 milligrams twice daily, or 60 milligrams once daily.
• Blood draws occurred at baseline, week 2, week 4, and week 12 to profile 2,841 proteins in each sample.
• All six models agreed on the biological age reduction, with the largest shift appearing at week 4 in the 30-milligram twice-daily cohort.

Biobank Comparison Shows Broad Protein Changes

Circulating proteins shifted by rentosertib overlapped heavily with systemic markers of human biological aging.

Researchers compared trial blood samples against genetic and protein profiles from 55,319 United Kingdom (UK) Biobank participants.

The two databases shared 2,832 measured proteins.

• Proteins altered by the drug were 1.74 times more likely to link to aging than chance dictates.
• This finding indicates that the molecule alters biological pathways well outside local lung tissue.
• Inhibiting TNIK appears to modify cellular processes shared by tissue fibrogenesis and general metabolic decline.

Small Sample Sizes Limit Immediate Clinical Application

Small patient cohorts and short observation periods mean rentosertib remains an unproven intervention for slowing biological age.

The Phase 2a trial followed only 42 individuals.

A 12-week study cannot determine whether temporary shifts in circulating proteins prevent chronic disease, maintain metabolic health, or extend human lifespan.

• Proteomic aging clocks act as research surrogates rather than verified clinical endpoints.
• Rentosertib is an investigational drug that lacks regulatory approval for IPF or age-related conditions.
• Individuals tracking metabolic biomarkers should discuss established nutritional and medical options with their clinician rather than pursuing unapproved kinase inhibitors.